[1]俞 臻,杨文莉,林 欣,等.心衰Ⅰ号方治疗阳虚水泛证射血分数保留型心衰临床研究[J].陕西中医,2025,46(2):201-205.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.011]
　YU Zhen,YANG Wenli,LIN Xin,et al.Clinical efficacy of No.1 Xinshuai formula in Yang deficiency and water flooding syndrome patients with HFpEF[J].,2025,46(2):201-205.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.011]
点击复制

心衰Ⅰ号方治疗阳虚水泛证射血分数保留型心衰临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年2期
页码:
201-205
栏目:
临床研究
出版日期:
2025-02-05

文章信息/Info

Title:
Clinical efficacy of No.1 Xinshuai formula in Yang deficiency and water flooding syndrome patients with HFpEF
作者:
俞 臻1; 杨文莉2; 林 欣3; 王令谆3; 赵云贺2; 包 桐2
(1.南京市第二医院,江苏 南京 210003; 2.南京中医药大学第一临床医学院,江苏 南京 210023; 3.南京中医药大学附属医院,江苏 南京 210029)
Author(s):
YU Zhen1; YANG Wenli2; LIN Xin3; WANG Lingzhun3; ZHAO Yunhe2; BAO Tong2
(1.The Second Hospital of Nanjing,Medical School of Nanjing University,Nanjing 210003,China; 2.The First Clinical Medical College of Nanjing University of Chinese Medicine,Nanjing 210023,China; 3.Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)
关键词:
射血分数保留型心衰;  心衰Ⅰ号方;  阳虚水泛;  心衰标志物;  炎症因子
Keywords:
Heart failure with preserved ejection fraction;  No.1 Xinshuai formula;  Yang deficiency and water flooding syndrome;  Heart function indexes;  Inflammatory factor
分类号:
R 541.6
DOI:
DOI:10.3969/j.issn.1000-7369.2025.02.011
文献标志码:
A
摘要:
目的:基于炎症因子白细胞介素-1β(IL-1β)、白细胞介素-18(IL-18)、高敏C反应蛋白(hs-CRP)、心衰标志物血清可溶性生长刺激表达基因2蛋白(sST2)、氨基末端脑钠肽前体(NT-proBNP)研究心衰I号方对射血分数保留型心衰(HFpEF)患者(阳虚水泛证)的临床疗效。方法:选择60例HFpEF心衰患者,均分为对照组和试验组各30例。对照组接受标准抗心衰治疗,试验组则在此基础上加用心衰Ⅰ号中药方剂。在治疗前及治疗14 d后,对两组患者中医症候进行评估,并监测sST2、NT-proBNP、IL-1β、IL-18及hs-CRP等指标变化。结果:治疗后两组患者的中医症候积分(单项及总分)和sST2水平均明显低于本组治疗前(P<0.05),且试验组较对照组均明显降低(P<0.05); 治疗后两组患者IL-1β和hs-CRP水平较治疗前均明显降低,且试验组IL-1β水平较对照组降低显著(P<0.01),试验组hs-CRP水平也显著低于对照组,差异具有统计学意义(P<0.05); 治疗后两组NT-proBNP和IL-18较治疗前下降(P<0.05),且试验组低于对照组。结论:心衰Ⅰ号方与标准抗心衰治疗联合应用,可以明显改善HFpEF患者的临床症候,改善心脏功能,其作用机制可能与抑制炎症反应相关。
Abstract:
Objective:To explore the effects of No.1 Xinshuai formula plus conventional based on heart failure markers sST2,NT-proBNP and inflammatory factors IL-1β,IL-18,hs-CRP in heart failure with preserved ejection fraction.Methods:60 patients with HFpEF heart failure were enrolled clinically and divided into control group and experimental group,30 cases each.The control group received standard anti-heart failure treatment,while the experimental group was treated with No.1 Xinshuai formula on this basis.Before treatment and after 14 days of treatment,the TCM evidence of the two groups was evaluated,and the changes of sST2,NT-proBNP,IL-1β,IL-18 and hs-CRP were monitored.Results:The TCM evidence scores(individual and total)and sST2 levels of the two sets after therapy were obviously reduced compared with those before therapy in this set(P<0.05),and both experimental sets were markedly less in comparison with the control set(P<0.05); IL-1β and hs-CRP levels were markedly less in both sets after therapy relative to pre-treatment levels,and the level of IL-1β in the experimental group was extremely decreased compared with that in the control group(P<0.01),the level of hs-CRP in the experimental group was also remarkably less than that in the control group,which was statistical significance(P<0.05); NT-proBNP and IL-18 declined substantially in two sets after therapy than before therapy(P<0.05),and they were both less in the experimental sets than in the control sets,but there was no apparent statutory meaning.Conclusion:No.1 Xinshuai formula,applied in combination with standard anti-heart failure treatment,can significantly improve the clinical evidence of HFpEF patients and improve cardiac function,and its mechanism of action may be related to the inhibition of inflammatory response.

参考文献/References:

[1] HUIS I V,DE MAN F S,VAN ROSSUM A C,et al.How to diagnose heart failure with preserved ejection fraction:The value of invasive stress testing[J].Neth Heart J,2016,24:244-251.
[2] LAM C S,DONAL E,KRAIQGHER K E,et al.Epidemiology and clinical course of heart failure with preserved ejection fraction[J].Eur J Heart Fail,2011,13(1):18-28.
[3] 刘蔚,尉然.射血分数保留的心力衰竭的诊断和治疗策略[J].中国全科医学,2021,24(3):253-258.
[4] 陈丽珍,杨雷,许锦文.淫羊藿苷通过NO-cGMP-PKG减轻炎症并改善射血分数保留型心衰大鼠的心室重塑[J].新中医,2024,56(3):209-216.
[5] OMOTE K,VERBRUGGE F H,BORLAUG B A.Heart failure with preserved ejection fraction:Mechanisms and treatment strategies[J].Annu Rev Med,2022,73(1):321-337.
[6] NEAL B,PERKOVIC V,MAHAFFEY K W,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.
[7] ANKER S D,BUTLER J,FILIPPATOS G,et al.Empagliflozin in heart failure with a preserved ejection fraction[J].N Engl J Med,2021,385(16):1451-1461.
[8] 贾晓艳,刘永铭.SGLT2i在射血分数保留心力衰竭中的作用研究进展[J].解放军医学杂志,2022,47(2):203-212.
[9] 浦强,王丽晓,唐海军,等.心衰1号方联合常规治疗对老年慢性心力衰竭(气虚血瘀证)患者心功能及炎症因子的影响[J].中医临床研究,2022,14(18):51-54.
[10] 国家心血管病中心,国家心血管病专家委员会心力衰竭专业委员会,中国医师协会心力衰竭专业委员会,等.国家心力衰竭指南2023[J].中华心力衰竭和心肌病杂志,2023,7(4):215-311.
[11] 陈可冀,吴宗贵,朱明军,等.慢性心力衰竭中西医结合诊疗专家共识[J].心脑血管病防治,2016,16(5):340-347.
[12] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:77-85.
[13] WINTRICH J,KINDERMANN I,UKENA C,et al.Therapeutic approaches in heart failure with preserved ejection fraction:Past,present,and future[J].Clin Res Cardiol,2020,109:1079-1098.
[14] KITZMAN D W,SHAH S J.The HFpEF obesity phenotype:The elephant in the room[J].J Am Coll Cardiol,2016,68(2):200-203.
[15] SHAH S J,LAM C S,SVEDLUND S,et al.Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction:PROMIS-HFpEF[J].Eur Heart J,2018,39(37):3439-3450.
[16] KHODAYARI S,KHODAYARI H,AMIRI A Z,et al.Inflammatory microenvironment of acute myocardial infarction prevents regeneration of heart with stem cells therapy[J].Cell Physiol Biochem,2019,53(5):887-909.
[17] 杜小琴,王燕侠,李霞,等.血清IL-18、IL-1β及NLRP3炎症小体在射血分数保留型心衰患者中的表达及其与肠道菌群的相关性分析[J].现代生物医学进展,2023,23(23):4492-4495.
[18] XIE M,XIE D,YANG Y,et al.Association of high-sensitivity C-reactive protein in middle-aged and elderly Chinese people with hyperuricaemia and risk of coronary heart disease:A cross-sectional study[J].BMJ Open,2019,9(10):28351.
[19] ZHUANG Q,SHEN C,CHEN Y,et al.Association of high sensitive C-reactive protein with coronary heart disease:A mendelian randomization study[J].BMC Med Genet,2019,20:1-7.
[20] WEINBERG E O.ST2 protein in heart disease:From discovery to mechanisms and prognostic value[J].Biomark Med,2009,3(5):495-511.
[21] KIM M S,JEONG T D,HAN S B,et al.Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency[J].J Korean Med Sci,2015,30(5):569-575.
[22] HAMAGAWA K,KUBO T,NISHIMURA K,et al.N-terminal pro-brain natriuretic peptide is a useful marker to identify latent heart failure patients in older adults in a rural outpatient clinic[J].Geriatr Gerontol Int,2017,17(10):1648-1653.
[23] 陶文祥,郑朝阳,孙海娇,等.国医大师邓铁涛从五脏相关学说论治射血分数保留型心力衰竭[J].中医学报,2020,35(11):2372-2375.
[24] 陈可冀,吴宗贵,朱明军,等.慢性心力衰竭中西医结合诊疗专家共识[J].中国中西医结合杂志,2016,36(2):133-141.
[25] 刘福明,李七一.李七一从痰瘀辨治慢性充血性心力衰竭经验[J].山东中医药大学学报,2011,35(4):327-328.
[26] 赵惠,李七一,张琪,等.心衰Ⅰ号对慢性收缩性心力衰竭的临床研究[J].南京中医药大学学报,2013,29(2):117-120.
[27] 张尚祖,刘永琦,李洋洋,等.黄芪防治心血管疾病的作用机制研究进展[J].中药药理与临床,2023,39(10):115-124.
[28] 焦增华,杨亚军,刘希望,等.蒲黄药理作用研究进展[J].中兽医医药杂志,2017,36(3):85-88.
[29] 刘萍,张丽萍.桂枝化学成分及心血管药理作用研究[J].辽宁中医杂志,2012,39(10):1926-1927.
[30] 周迎春,张廉洁,张燕丽.山茱萸化学成分及药理作用研究新进展[J].中医药信息,2020,37(1):114-120.

备注/Memo

备注/Memo:
[基金项目]江苏省中医药科技发展计划项目(YB2020007)
更新日期/Last Update: 2025-02-08